Latest Ratios: P/E Ratio 279.6x · EV/EBITDA 41.0x · ROE 4.2%. (2004–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $610M | $728M | $1.2B | $1.7B | $602M | $418M | $1.8B | $1.2B | $1.3B | $701M | $114M |
| Enterprise Value | $574M | $692M | $1.2B | $1.7B | $577M | $376M | $1.8B | $1.2B | $1.3B | $691M | $123M |
| P/E Ratio → | 279.56 | 313.78 | 242.00 | — | 265.00 | — | — | — | — | — | — |
| P/S Ratio | 5.23 | 6.25 | 11.70 | 14.91 | 5.88 | 57.00 | 86.66 | — | 221193.86 | 688.14 | 285.46 |
| P/B Ratio | 4.56 | 5.12 | 12.58 | 121.24 | 8.33 | 10.18 | 23.86 | 17.94 | 11.06 | 22.76 | 7.09 |
| P/FCF | — | — | — | 97.72 | 105.95 | — | — | — | — | — | — |
| P/OCF | 604.05 | 721.24 | — | 65.32 | 56.36 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.94 | 11.61 | 14.62 | 5.64 | 51.28 | 85.29 | — | 215991.70 | 678.92 | 308.36 |
| EV / EBITDA | 40.97 | 49.41 | 69.15 | — | 55.86 | — | — | — | — | — | — |
| EV / EBIT | 49.95 | 60.25 | 75.64 | 86.30 | 62.71 | — | — | — | — | — | — |
| EV / FCF | — | — | — | 95.81 | 101.63 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.4% | 95.4% | 96.3% | 95.9% | 95.3% | -4.5% | 56.3% | — | -357800.0% | -1162.0% | -2545.4% |
| Operating Margin | 9.9% | 9.9% | 15.3% | -59.3% | 9.0% | -1141.0% | -273.9% | — | -563700.0% | -2143.6% | -5117.3% |
| Net Profit Margin | 4.3% | 4.3% | 11.4% | -81.9% | 2.3% | -1198.3% | -265.1% | — | -500916.7% | -2118.0% | -4246.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.2% | 4.2% | 21.5% | -215.7% | 4.1% | -150.1% | -76.9% | -58.6% | -39.9% | -92.1% | -71.4% |
| ROA | 3.4% | 3.4% | 10.0% | -92.3% | 3.3% | -116.8% | -57.4% | -49.4% | -36.6% | -55.6% | -31.5% |
| ROIC | 8.9% | 8.9% | 35.1% | -353.8% | 29.5% | -270.2% | -84.3% | -59.9% | -46.1% | -70.2% | -50.0% |
| ROCE | 9.1% | 9.1% | 16.0% | -79.6% | 16.1% | -141.3% | -78.2% | -60.4% | -44.8% | -93.1% | -85.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.02 | 0.03 | 0.01 | 0.06 | 0.02 | 0.03 | — | 0.17 | 1.21 |
| Debt / EBITDA | 0.07 | 0.07 | 0.09 | — | 0.06 | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.25 | -0.10 | -2.37 | -0.34 | -1.02 | -0.38 | -0.20 | -0.26 | -0.31 | 0.57 |
| Net Debt / EBITDA | -2.58 | -2.58 | -0.58 | — | -2.38 | — | — | — | — | — | — |
| Debt / FCF | — | — | — | -1.91 | -4.33 | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($37M) exceeds total debt ($939000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.60 | 5.60 | 3.32 | 2.85 | 4.06 | 3.63 | 5.03 | 3.32 | 25.83 | 4.48 | 1.71 |
| Quick Ratio | 5.04 | 5.04 | 2.99 | 2.64 | 3.56 | 3.63 | 5.03 | 3.32 | 25.83 | 3.87 | 0.82 |
| Cash Ratio | 2.87 | 2.87 | 1.37 | 1.67 | 2.06 | 3.31 | 4.46 | 2.66 | 25.02 | 3.71 | 0.78 |
| Asset Turnover | — | 0.70 | 0.84 | 0.97 | 1.21 | 0.13 | 0.22 | — | 0.00 | 0.03 | 0.01 |
| Inventory Turnover | 0.53 | 0.53 | 0.61 | 1.08 | 0.78 | — | — | — | — | 2.42 | 0.54 |
| Days Sales Outstanding | — | 115.67 | 100.62 | 54.18 | 55.72 | 90.43 | 57.73 | — | — | 8.61 | 28.36 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | 0.6% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.4% | 0.3% | 0.4% | — | 0.4% | — | — | — | — | — | — |
| FCF Yield | — | — | — | 1.0% | 0.9% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.6% | 0.0% |
| Shares Outstanding | — | $103M | $102M | $66M | $76M | $31M | $19M | $12M | $11M | $3M | $778780 |
Geopolitical and regulatory concentration
According to current market data, Gyre trades at a P/S ratio of 5.23 and an EV/EBITDA of 40.97, suggesting that investors are pricing in significant future growth from the F351 pipeline rather than relying on the current, volatile revenue stream from ETUARY.
The elevated EV/EBITDA multiple relative to peers indicates that the market is assigning a premium to the company's clinical-stage potential despite the lack of consistent profitability. Investors should monitor whether this valuation holds if clinical milestones for F351 face delays, as the current multiple appears to leave little room for execution errors.
Based on reported figures, ROIC has fluctuated wildly from a peak of 30.2% in 2024Q1 to a negative 6.8% in 2026Q1, illustrating that the company has yet to establish a stable, compounding return profile on its invested capital base.
The extreme volatility in ROIC suggests that the company's capital allocation is heavily influenced by non-recurring charges and the timing of clinical trial expenditures. This inconsistency warrants further investigation into whether the firm can generate sustainable returns once the F351 asset moves into a more mature commercial phase.
As reported in financial statements, the company's cash conversion cycle remains exceptionally long, peaking at 894 days in 2026Q1, which highlights significant inefficiencies in inventory management and the extended time required to convert clinical-stage assets into realized cash flow.
The high DIO and DSO figures suggest that Gyre faces structural challenges in managing its working capital, likely exacerbated by the complexities of the Chinese pharmaceutical distribution environment. This inefficiency forces the company to maintain higher liquidity buffers than would otherwise be necessary for a firm with such high gross margins.
Based on recent quarterly filings, the company maintains a current ratio of 4.64, providing a substantial liquidity cushion that appears sufficient to support ongoing Phase 3 clinical trial enrollment despite the absence of consistent positive free cash flow generation.
The strong current ratio indicates that the company is well-positioned to meet its short-term obligations, reducing the immediate risk of a liquidity crisis. However, investors should monitor the quick ratio, which remains elevated, as it suggests a significant portion of current assets is tied up in inventory that may not be easily liquidated.
As indicated by the company's financial data, the P/E ratio of 279.56 is a fundamentally misleading metric for Gyre, as it fails to account for the heavy R&D investment and non-recurring accounting charges that currently suppress net income.
Using P/E to value a company in this stage of development obscures the underlying earning power of the commercialized ETUARY asset. Analysts should instead focus on EV/Sales or adjusted EBITDA metrics to better capture the value of the company's core commercial operations and its pipeline potential.
Includes 30+ ratios · 22 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GYRE stock.
Gyre Therapeutics, Inc.'s current P/E ratio is 279.6x. This places it at the 50th percentile of its historical range.
Gyre Therapeutics, Inc.'s current EV/EBITDA is 41.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 58.1x.
Gyre Therapeutics, Inc.'s return on equity (ROE) is 4.2%. The historical average is -45.2%.
Based on historical data, Gyre Therapeutics, Inc. is trading at a P/E of 279.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Gyre Therapeutics, Inc. has 95.4% gross margin and 9.9% operating margin.
Gyre Therapeutics, Inc.'s Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.